Avacta Group (AVCT)

 

Latest News

Covance to present Affimer data at forum says Avacta

Avacta, the developer of Affimer biotherapeutics and reagents, has announced that Covance will be presenting Affimer d...

Covance to Present Affimer Data at Conference

RNS Number: 4911W Avacta Group PLC 15 November 2017 15 November 2017 Avacta Group plc ("Avacta", "the Group" or "the Company") Covance to Present Affimer Data at European Conference Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that Covance will be presenting Affimer data from a j...

Holding(s) in Company

RNS Number: 4901W Avacta Group PLC 14 November 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Avacta Group ...

Avacta to present at PEGS Europe

Avacta Group chief scientific officer, Dr Amrik Basran, will be presenting an update on the Affimer therapeutics program...

All News

DateHeadlineSource
15-11-17Covance to present Affimer data at forum says AvactaStockMarketWire
15-11-17Covance to Present Affimer Data at ConferenceRNS
14-11-17Holding(s) in CompanyRNS
13-11-17Avacta to present at PEGS EuropeStockMarketWire
13-11-17Avacta to Present at Investor EveningRNS
13-11-17Avacta to present at PEGS EuropeRNS
24-10-17Record Year for Affimers in scientific publications, says Avacta StockMarketWire
24-10-17Affimers in Scientific PublicationsRNS
19-10-17Private Shareholder Update EventRNS
16-10-17Hardman Res.: R&D accelerated to advance assetsRNS
12-10-17Avacta to present at Shares Spotlight EveningStockMarketWire
12-10-17Avacta to Present at Shares Spotlight EveningRNS
10-10-17Avacta to present at the Shares Spotlight Evening in London on 19 October 2017StockMarketWire
10-10-17Avacta CTO to present at US conference StockMarketWire
10-10-17Avacta to Present at Major US ConferenceRNS
09-10-17Director Dealing and Issue of EquityRNS
05-10-17Avacta research collaboration with FIT BiotechStockMarketWire
05-10-17Research collaboration with FIT Biotech OyRNS
04-10-17Avacta revenues rise but losses widen StockMarketWire
04-10-17Preliminary ResultsRNS
02-10-17Avacta establishes US business development teamStockMarketWire
02-10-17Avacta establishes US business development teamRNS
07-09-17Notice of ResultsRNS
21-08-17Director Deals - Avacta Group PLC (AVCT)StockMarketWire
21-08-17Director/PDMR ShareholdingRNS
07-08-17Avacta revenues rise StockMarketWire
07-08-17Trading UpdateRNS
31-07-17Issue of EquityRNS
28-07-17Director/PDMR ShareholdingRNS
05-07-17Director Dealing and Issue of EquityRNS
04-07-17Manchester ShareSoc Growth Company SeminarRNS
05-06-17ShareSoc Growth Company SeminarRNS
01-06-17Issue of EquityRNS
22-05-172 Biotech's Licence Affimers for Research UseRNS
10-05-17Avacta to be granted patent in China StockMarketWire
08-05-17Moderna releases Phase I trial data for mRNA technologyStockMarketWire
08-05-17Hardman Research: De-risking Moderna's partnershipRNS
05-05-17Avacta CEO to present at Hardman forum StockMarketWire
05-05-17Presenting at the Hardman Private Investor ForumRNS
02-05-17Avacta to Present at BioTrinity 2017RNS

RSS feeds

  • Editorial news feed for LSE:AVCT Editorial
  • Regulatory news feed for LSE:AVCT Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account